These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 25388285)
41. Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Tanaka K; Ishikawa S; Matsui Y; Kawanishi T; Tamesada M; Harashima N; Harada M Cancer Immunol Immunother; 2012 Nov; 61(11):2143-52. PubMed ID: 22588648 [TBL] [Abstract][Full Text] [Related]
42. Artificially synthesized helper/killer-hybrid epitope long peptide (H/K-HELP): preparation and immunological analysis of vaccine efficacy. Masuko K; Wakita D; Togashi Y; Kita T; Kitamura H; Nishimura T Immunol Lett; 2015 Jan; 163(1):102-12. PubMed ID: 25479286 [TBL] [Abstract][Full Text] [Related]
43. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Hangalapura BN; Oosterhoff D; Gupta T; de Groot J; Wijnands PG; van Beusechem VW; den Haan J; Tüting T; van den Eertwegh AJ; Curiel DT; Scheper RJ; de Gruijl TD Vaccine; 2011 Mar; 29(12):2313-21. PubMed ID: 21272606 [TBL] [Abstract][Full Text] [Related]
44. The combination of ISCOMATRIX adjuvant and TLR agonists induces regression of established solid tumors in vivo. Silva A; Mount A; Krstevska K; Pejoski D; Hardy MP; Owczarek C; Scotney P; Maraskovsky E; Baz Morelli A J Immunol; 2015 Mar; 194(5):2199-207. PubMed ID: 25646304 [TBL] [Abstract][Full Text] [Related]
45. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048 [TBL] [Abstract][Full Text] [Related]
46. Regulation of the activity of an adeno-associated virus vector cancer vaccine administered with synthetic Toll-like receptor agonists. Triozzi PL; Aldrich W; Ponnazhagan S Vaccine; 2010 Nov; 28(50):7837-43. PubMed ID: 20937315 [TBL] [Abstract][Full Text] [Related]
47. Nano-adjuvants and immune agonists promote antitumor immunity of peptide amphiphiles. Yan H; Lin G; Liu Z; Gu F; Zhang Y Acta Biomater; 2023 Apr; 161():213-225. PubMed ID: 36858163 [TBL] [Abstract][Full Text] [Related]
48. A Dual-Color Bioluminescence Reporter Mouse for Simultaneous Kleinovink JW; Mezzanotte L; Zambito G; Fransen MF; Cruz LJ; Verbeek JS; Chan A; Ossendorp F; Löwik C Front Immunol; 2018; 9():3097. PubMed ID: 30671062 [TBL] [Abstract][Full Text] [Related]
49. Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. Kreiter S; Selmi A; Diken M; Koslowski M; Britten CM; Huber C; Türeci O; Sahin U Cancer Res; 2010 Nov; 70(22):9031-40. PubMed ID: 21045153 [TBL] [Abstract][Full Text] [Related]
50. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Perret R; Sierro SR; Botelho NK; Corgnac S; Donda A; Romero P Cancer Res; 2013 Nov; 73(22):6597-608. PubMed ID: 24048821 [TBL] [Abstract][Full Text] [Related]
51. Extralymphatic tumors prepare draining lymph nodes to invasion via a T-cell cross-tolerance process. Preynat-Seauve O; Contassot E; Schuler P; Piguet V; French LE; Huard B Cancer Res; 2007 May; 67(10):5009-16. PubMed ID: 17510433 [TBL] [Abstract][Full Text] [Related]
52. Effective cooperation of monoclonal antibody and peptide vaccine for the treatment of mouse melanoma. Ly LV; Sluijter M; van der Burg SH; Jager MJ; van Hall T J Immunol; 2013 Jan; 190(1):489-96. PubMed ID: 23203930 [TBL] [Abstract][Full Text] [Related]
53. Antigen delivery for cross priming via the emulsion vaccine adjuvants. Shen SS; Yang YW Vaccine; 2012 Feb; 30(9):1560-71. PubMed ID: 22230588 [TBL] [Abstract][Full Text] [Related]
54. Antitumor effect of adenoviral vector prime protein boost immunity targeting the MUC1 VNTRs. Wang Y; Liu C; Xia Q; Wang P; Li B; Lu Z; Sun J; Wu H; Yu B; Wu J; Yu X; Kong W; Zhang H; Cong X Oncol Rep; 2014 Mar; 31(3):1437-44. PubMed ID: 24378623 [TBL] [Abstract][Full Text] [Related]
55. Adjuvants may reduce in vivo transfection levels for DNA vaccination in mice leading to reduced antigen-specific CD8+ T cell responses. Rose AH; Hoffmann FW; Hara JH; Urschitz J; Moisyadi S; Hoffmann PR; Bertino P Hum Vaccin Immunother; 2015; 11(9):2305-11. PubMed ID: 26091088 [TBL] [Abstract][Full Text] [Related]
56. In situ engineering of the lymph node microenvironment via intranodal injection of adjuvant-releasing polymer particles. Jewell CM; López SC; Irvine DJ Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15745-50. PubMed ID: 21896725 [TBL] [Abstract][Full Text] [Related]
57. Construction of lymph nodes-targeting tumor vaccines by using the principle of DNA base complementary pairing to enhance anti-tumor cellular immune response. Zha Y; Fu L; Liu Z; Lin J; Huang L J Nanobiotechnology; 2024 May; 22(1):230. PubMed ID: 38720322 [TBL] [Abstract][Full Text] [Related]
58. Immunization with tumor neoantigens displayed on T7 phage nanoparticles elicits plasma antibody and vaccine-draining lymph node B cell responses. Shukla GS; Sun YJ; Pero SC; Sholler GS; Krag DN J Immunol Methods; 2018 Sep; 460():51-62. PubMed ID: 29906453 [TBL] [Abstract][Full Text] [Related]
59. Unique depot formed by an oil based vaccine facilitates active antigen uptake and provides effective tumour control. Brewer KD; Weir GM; Dude I; Davis C; Parsons C; Penwell A; Rajagopalan R; Sammatur L; Bowen CV; Stanford MM J Biomed Sci; 2018 Jan; 25(1):7. PubMed ID: 29374458 [TBL] [Abstract][Full Text] [Related]
60. Anticancer Vaccination with Immunogenic Micelles That Capture and Release Pristine CD8 Ren H; Li J; Liu G; Sun Y; Yang X; Jiang Z; Zhang J; Lovell JF; Zhang Y ACS Appl Mater Interfaces; 2022 Jan; 14(2):2510-2521. PubMed ID: 34986639 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]